Crucell N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 02 nov 2007 - 08:01

Statutaire naam Crucell N.V.

Titel DSM Biologics and Crucell Announce PER.C6® Technology Licensing Agreement with Recepta Biopharma S.A.

Bericht Sittard/Leiden, The Netherlands, November 2, 2007 – DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that they have signed a non-exclusive PER.C6® technology research licensing agreement with Brazilian-based Recepta Biopharma S.A. This agreement allows Recepta Biopharma to use the PER.C6® technology to develop four antibodies it has licensed-in from the Ludwig Institute for Cancer Research. Financial details were not disclosed.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

200711020000000006_Recepta Biopharma_FINAL.pdf (opens in a new window)

Datum laatste update: 01 september 2024